文献速递免疫规划

一项在65岁及以上成人中评估佐剂三价亚单位流感疫苗安全性和免疫原性的1期随机观察者盲法抗原与佐剂剂量探索临床试验

A phase 1, randomized, observer blind, antigen and adjuvant dosage finding clinical trial to evaluate the safety and immunogenicity of an adjuvanted, trivalent subunit influenza vaccine in adults ≥ 65 years of age.
PubMed 文献 · Vaccine · 2019-11-01

该1期随机观察者盲法试验将196名65岁及以上成人随机分配接受7种不同佐剂和抗原剂量的MF59佐剂三价流感疫苗(aTIV;Fluad)单次或分两次注射,主要比较接种21天后血清学反应,并随访免疫原性和安全性一年。结果显示,含最高佐剂和抗原剂量的组6免疫反应最高,但局部反应原性发生率也随剂量增加。

要点

  • 组6接种21天后对A/H1N1、A/H3N2和B株的HI抗体GMT分别为382.2、552.3和54.1。
  • 组6血清转化率对A/H1N1、A/H3N2和B株分别为75%、75%和42.9%。
  • 最高抗原剂量与最高佐剂剂量同部位接种的组4和组6报告征集性不良事件发生率分别为67.9%和57.1%。

核心结论

  • 在65岁及以上成人中,与已上市aTIV相比增加佐剂和抗原剂量,MF59剂量增加可提高对季节性流感疫苗全部3个组分的免疫原性。
  • 免疫原性增加伴随局部反应原性发生率增加。

研究设计与样本

  • 1期随机观察者盲法临床试验,共纳入196名65岁及以上受试者,随机接受7种不同佐剂和抗原剂量的疫苗配方,单次注射或同一时间点分两次注射。
  • 主要研究目标为比较接种21天后不同aTIV配方的血清学反应,受试者随访免疫原性和安全性一年。

主要发现

  • 接种3周后,组6的HI抗体GMT最高:对A/H1N1为382.2(95%CI 237.5至615.0),对A/H3N2为552.3(95%CI 364.8至836.1),对B为54.1(95%CI 36.9至79.4)。
  • 组6血清转化率对A/H1N1为75%(95%CI 55.1至89.3),对A/H3N2为75%(95%CI 55.1至89.3),对B为42.9%(95%CI 24.5至62.8)。
  • 最高抗原剂量与最高佐剂剂量同部位接种的组4和组6报告征集性不良事件发生率最高,分别为67.9%和57.1%。
  • 大多数征集性不良事件为轻至中度,不同剂量间非征集性不良事件数量相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the safety and immunogenicity of the MF59®-adjuvanted trivalent influenza vaccine (aTIV; Fluad®) compared with modified aTIV formulations. METHODS: A total of 196 subjects ≥ 65 years were randomized to receive7different formulations of vaccine containing a range of adjuvant and antigen dosesby single injection, or divided into two injections at a single time point. The primary study objective was to compare the serologic response of different formulations of aTIV containing increased amounts of adjuvant and antigen21 days after vaccination. Subjects were followed for immunogenicity and safety for one year. RESULTS: The highest immune response, as measured by hemagglutination inhibition (HI) assay, 3 weeks after vaccination was observed in subjects in Group 6 with GMT 382.2 (95% confidence interval [CI] 237.5 to 615.0), 552.3 (364.8 to 836.1), and 54.1 (36.9 to 79.4) against A/H1N1, A/H3N2, and B respectively. Rates of seroconversion were also generally highest in this treatment group: 75% (95% CI 55.1 to 89.3), 75% (55.1 to 89.3), and 42.9% (24.5 to 62.8), respectively, against A/H1N1, A/H3N2, and B strains. The highest incidence of solicited adverse events (AEs) was reported by subjects who received both the highest dosage of antigen in combination with the highest dosage of adjuvant at the same site: 67.9% and 57.1% in Groups 4 and 6, respectively. The majority of solicited AEs were mild to moderate in severity. The number of unsolicited AEs was similar across the different dosages. CONCLUSION: In this phase I trial of adults ≥ 65 years of age who received increased adjuvant and antigen dosages relative to the licensed aTIV, increased dosage of MF59 resulted in increased immunogenicity against all 3 components of seasonal influenza vaccine. The increase in immunogenicity was accompanied by an increase in the incidence of local reactogenicity.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Otten G, Matassa V, Ciarlet M, et al. A phase 1, randomized, observer blind, antigen and adjuvant dosage finding clinical trial to evaluate the safety and immunogenicity of an adjuvanted, trivalent subunit influenza vaccine in adults ≥ 65 years of age. Vaccine. 2019. PMID: 31679865. doi:10.1016/j.vaccine.2019.10.058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。